Anti-Cancer Effects of Glaucarubinone in the Hepatocellular Carcinoma Cell Line Huh7 via Regulation of the Epithelial-To-Mesenchymal Transition-Associated Transcription Factor Twist1.


Journal

International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791

Informations de publication

Date de publication:
08 Feb 2021
Historique:
received: 29 12 2020
revised: 30 01 2021
accepted: 04 02 2021
entrez: 11 2 2021
pubmed: 12 2 2021
medline: 13 4 2021
Statut: epublish

Résumé

Hepatocellular carcinoma (HCC), the most common type of liver cancer, is a leading cause of cancer-related deaths. As HCC has a high mortality rate and its incidence is increasing worldwide, understanding and treating HCC are crucial for resolving major public health concerns. In the present study, wound healing screening assays were performed using natural product libraries to identify natural chemicals that can inhibit cancer cell migration. Glaucarubinone (GCB) showed a high potential for inhibiting cell migration. The anti-cancer effects of GCB were evaluated using the HCC cell line, Huh7. GCB showed anti-cancer effects, as verified by wound healing, cell migration, invasion, colony formation, and three-dimensional spheroid invasion assays. In addition, cells treated with GCB showed suppressed matrix metalloproteinase activities. Immunoblotting analyses of intracellular signaling pathways revealed that GCB regulated the levels of Twist1, a crucial transcription factor associated with epithelial-to-mesenchymal transition, and mitogen-activated protein kinase. The invasive ability of cancer cells was found to be decreased by the regulation of Twist1 protein levels. Furthermore, GCB downregulated phosphorylation of extracellular signal-regulated kinase. These results indicate that GCB exhibits anti-metastatic properties in Huh7 cells, suggesting that it could be used to treat HCC.

Identifiants

pubmed: 33567682
pii: ijms22041700
doi: 10.3390/ijms22041700
pmc: PMC7915236
pii:
doi:

Substances chimiques

Antineoplastic Agents 0
Biomarkers, Tumor 0
Nuclear Proteins 0
TWIST1 protein, human 0
Twist-Related Protein 1 0
glaucarubinone 1259-86-5
Glaucarubin EH6H7VS52J

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : National Research Foundation of Korea
ID : NRF2018R1A2B6005084
Organisme : National Research Foundation of Korea
ID : 2015R1A5A1008958

Références

Cell Syst. 2019 Aug 28;9(2):109-127
pubmed: 31465728
Nat Rev Cancer. 2003 May;3(5):362-74
pubmed: 12724734
J Pharm Bioallied Sci. 2015 Apr;7(Suppl 1):S181-3
pubmed: 26015704
Curr Cancer Drug Targets. 2019;19(11):885-895
pubmed: 31215378
PLoS One. 2012;7(9):e44093
pubmed: 22970166
Oncogene. 2007 May 14;26(22):3279-90
pubmed: 17496922
Planta Med. 1984 Jun;50(3):261-3
pubmed: 17340307
Cancer Res. 2011 Jun 1;71(11):3980-90
pubmed: 21502402
Nat Rev Cancer. 2002 Mar;2(3):161-74
pubmed: 11990853
Biochim Biophys Acta. 2015 Jan;1853(1):157-65
pubmed: 25409929
J Nat Prod. 2009 Mar 27;72(3):503-6
pubmed: 19199792
Anal Cell Pathol (Amst). 2019 Nov 26;2019:9423907
pubmed: 31886121
Cancer Res. 2009 Sep 1;69(17):6987-94
pubmed: 19706755
Nephrol Dial Transplant. 2012 Nov;27(11):4119-24
pubmed: 22498918
Cell. 2017 Feb 9;168(4):670-691
pubmed: 28187288
Oncotarget. 2016 Jul 5;7(27):42353-42373
pubmed: 27304668
Oncogene. 2009 Aug 6;28(31):2796-805
pubmed: 19483725
J Nat Prod. 2010 Sep 24;73(9):1553-8
pubmed: 20738103
J Cell Biol. 1991 Apr;113(1):173-85
pubmed: 2007622
Cancer Lett. 2013 Aug 9;336(1):167-73
pubmed: 23623921
Cancer Lett. 2014 May 1;346(2):264-72
pubmed: 24491405
Asian Pac J Cancer Prev. 2013;14(9):5055-60
pubmed: 24175775
Oncogene. 2005 Dec 15;24(56):8277-90
pubmed: 16116478
Lung Cancer. 2006 Dec;54(3):309-17
pubmed: 16996643
Cell Death Dis. 2020 Aug 14;11(8):632
pubmed: 32801343
EMBO J. 1995 Dec 15;14(24):6107-15
pubmed: 8557030
Int J Mol Med. 2015 Sep;36(3):645-52
pubmed: 26133118
Mol Oncol. 2017 Jul;11(7):805-823
pubmed: 28599100
Cancer Discov. 2012 Mar;2(3):248-59
pubmed: 22585995
Exp Ther Med. 2013 Jul;6(1):97-100
pubmed: 23935727
Oncogene. 2015 Oct;34(43):5447-59
pubmed: 25684140
Oncol Rep. 2009 May;21(5):1323-33
pubmed: 19360311
Biomed Res Int. 2014;2014:921564
pubmed: 25197668
J Invest Surg. 2016 Dec;29(6):366-372
pubmed: 27027695
Gastroenterology. 2004 Nov;127(5 Suppl 1):S5-S16
pubmed: 15508102
Int J Mol Sci. 2012;13(1):142-72
pubmed: 22312244

Auteurs

Jihye Seo (J)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Jain Ha (J)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Eunjeong Kang (E)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Haelim Yoon (H)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Sewoong Lee (S)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Shi Yong Ryu (SY)

Korea Research Institute of Chemical Technology (KRICT), Daejeon 34114, Korea.

Kwonseop Kim (K)

College of Pharmacy and Research Institute for Drug Development, Chonnam National University, Gwangju 61186, Korea.

Sayeon Cho (S)

Laboratory of Molecular and Pharmacological Cell Biology, College of Pharmacy, Chung-Ang University, Seoul 06974, Korea.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH